Rothschild & Co announces completion of Redburn and Atlantic Equities merger into Redburn Atlantic


Global finance giant Rothschild & Co solidified its position in the market with the finalized merger of Redburn (Europe) Limited (Redburn) and Atlantic Equities LLP, as previously announced on 26 April 2023. With its central operations located in London, the newly-formed Redburn Atlantic endeavors to provide its clientele with comprehensive research coverage, unparalleled corporate access, expert research sales, and superior agency execution skills.

A hallmark feature of Redburn Atlantic is its innovative positioning of both US and European research under a single umbrella in London. This global industrial stratagem ensures the firm can cater to roughly 700 institutional investors globally. Integral to its expansive network are distribution teams spread across prime locations such as London, New York, Boston, Paris, Frankfurt, Geneva, and Madrid. The combined expertise of Redburn Atlantic is reflected in its formidable staff comprising over 90 research analysts, 43 in distribution, and 14 dedicated to corporate access.

See also  ADM to acquire Algar Agro’s Brazilian oilseeds facilities

Tapping into the legacy of its predecessors, Redburn Atlantic will further enhance its corporate access programs. A testament to its prowess, the merged entities jointly hosted over 400 corporate and specialist events and showcased nearly 40% of the S&P 500 by market capitalization in Europe during 2022.

Under the aegis of Rothschild & Co, Redburn Atlantic is positioned to spearhead equity capital market executions. This encompasses client participations in IPOs, placements, and block trades.

See also  Saint-Gobain plans $235m expansion for Palatka gypsum facility in Florida

Reflecting on the merger’s significance, Richard Wyatt, Partner and Chairman of Equity Markets Solutions at Rothschild & Co, remarked, “Redburn Atlantic’s inception strengthens the market intelligence available to our diverse client groups. It promises an unmatched blend of top-tier research coupled with stellar execution capabilities catering to both European and US equity investors.”

See also  AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer

Adam Young, who helms the position of CEO at Redburn Atlantic, added his perspective, “Our core lies in differentiated research, timely insights from the IDEAS1 systematic service, expansive corporate access, capital markets opportunities, and unparalleled execution. Our holistic offerings underscore our commitment to empower clients globally to optimize their investment strategies.”

Share This


Wordpress (0)